These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26507242)

  • 1. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    Murray NP; Aedo S; Reyes E; Orellana N; Fuentealba C; Jacob O
    BJU Int; 2016 Oct; 118(4):556-62. PubMed ID: 26507242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
    Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
    Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3375-3381. PubMed ID: 30583343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1577-1583. PubMed ID: 29936782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(16):7123-7. PubMed ID: 26514500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Dueñas R
    Arch Esp Urol; 2014 Oct; 67(8):684-91. PubMed ID: 25306986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort.
    Tilki D; Mandel P; Schlomm T; Chun FK; Tennstedt P; Pehrke D; Haese A; Huland H; Graefen M; Salomon G
    J Urol; 2015 Jun; 193(6):1970-5. PubMed ID: 25498570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
    Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.
    Beckmann K; O'Callaghan M; Vincent A; Roder D; Millar J; Evans S; McNeil J; Moretti K
    ANZ J Surg; 2018 Mar; 88(3):E183-E188. PubMed ID: 28471003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
    Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
    Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
    Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P
    Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy.
    Punnen S; Freedland SJ; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Carroll PR; Cooperberg MR
    Eur Urol; 2014 Jun; 65(6):1171-7. PubMed ID: 23587869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the Presence of Primary Circulating Prostate Cells Imply the Presence of Agressive Prostate Cancer with Early Biochemical Failure: a Comparison with the Walz Nomogram.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Orellana S; Jacob O
    Asian Pac J Cancer Prev; 2016; 17(7):3089-93. PubMed ID: 27509934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.
    Zhao KH; Hernandez DJ; Han M; Humphreys EB; Mangold LA; Partin AW
    Urology; 2008 Aug; 72(2):396-400. PubMed ID: 18372031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.
    Tamblyn DJ; Chopra S; Yu C; Kattan MW; Pinnock C; Kopsaftis T
    BJU Int; 2011 Nov; 108 Suppl 2():51-6. PubMed ID: 22085129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA density does not improve predictive accuracy of the UCSF-CAPRA score.
    Parker R; Bell A; Chang K; Greenberg S; Washington SL; Cowan JE; Carroll PR; Cooperberg MR
    Prostate; 2023 Jul; 83(10):922-928. PubMed ID: 37078628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head to Head Comparison of the Chun Nomogram, Percentage Free PSA and Primary Circulating Prostate Cells to Predict the Presence of Prostate Cancer at Repeat Biopsy.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2016; 17(6):2941-6. PubMed ID: 27356715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Urol J; 2020 May; 17(3):262-270. PubMed ID: 31912475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.